B7-H3与肺腺癌EGFR-TKI靶向治疗继发性耐药的相关性研究  

Study on the correlation between B7-H3 and acquired drug resistance of EGFR-TKI targeted therapy in lung adenocarcinoma

作　　者：杨英 丁萌 唐伟 刘欢欢 樊星语 陈礼文[1] Yang Ying;Ding Meng;Tang Wei;Liu Huanhuan;Fan Xingyu;Chen Liwen(Dept of Clinical Laboratory,The Second Affiliated Hospital of Anhui Medical University,Hefei 230601;Dept of Clinical Laboratory,Nanjing Hospital affiliated to Nanjing University of Chinese Medicine,Nanjing 210023)

机构地区：[1]安徽医科大学第二附属医院检验科,合肥230601 [2]南京中医药大学附属南京医院检验科,南京210023

出　　处：《安徽医科大学学报》2022年第9期1490-1493,1498,共5页Acta Universitatis Medicinalis Anhui

基　　金：安徽省自然科学基金(编号:1808085MH229);安徽省科技厅重点研发项目(编号:202004j07020027)。

摘　　要：目的探讨共信号分子B7-H3与肺腺癌表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)靶向治疗继发性耐药的相关性。方法采用免疫组化方法检测56例肺腺癌组织B7-H3表达,将其分为低表达和高表达两组,比较两组患者EGFR-TKI靶向治疗继发性耐药发生比例和发生时间;体外诱导培养吉非替尼耐药的EGFR突变肺腺癌细胞株H3255和HCC827,以野生型细胞株作为对照,流式细胞术分析耐药株B7-H3表达水平。结果56例肺腺癌患者中B7-H3低表达31例,高表达25例;截止该研究观察终止时间,B7-H3低表达和高表达患者继发性耐药发生例数分别为12例(38.7%)和14例(56.0%)(P=0.19,χ^(2)=1.663),其中位耐药时间分别为13.2个月和5.1个月(P=0.004,t=3.193);与野生型H3255和HCC827细胞株比较,耐药株B7-H3表达水平进一步增加。结论B7-H3表达水平与肺腺癌EGFR-TKI靶向治疗继发性耐药存在相关性。Objective To investigate the correlation between co-signaling molecule B7-H3 and epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)target therapy in acquired drug resistance of lung adenocarcinoma.Methods Immunohistochemical method was used to detect B7-H3 expression in 56 lung adenocarcinoma patients,and the cohort was divided into low and high B7-H3 expression groups.The proportion and occurrence time of acquired drug resistance after EGFR-TKI targeted therapy were compared between the two groups.Gefitinib-resistant EGFR mutant lung adenocarcinoma cell lines H3255 and HCC827 were induced and cultured in vitro.The wild-type cell lines were used as control,and the expression level of B7-H3 on resistant cell lines B7-H3 was analyzed by flow cytometry.Results In 56 lung adenocarcinoma patients,31 cases and 25 cases had low and high B7-H3 expression,respectively.By the end of this study,the cases of acquired drug resistance in patients with low and high B7-H3 expression were 12 cases(38.7%)and 14 cases(56.0%)(P=0.19,χ^(2)=1.663),and the median drug resistance time was 13.2 months and 5.1 months(P=0.004,t=3.193),respectively.Compared with wild-type H3255 and HCC827 cell lines,the expression level of drug-resistant strain B7-H3 further increased.Conclusion B7-H3 expression level is correlated with acquired drug resistance of EGFR-TKI targeted therapy in lung adenocarcinoma.

关 键 词：非小细胞肺癌 腺癌 EGFR-TKI B7-H3 耐药 

分 类 号：R734.2[医药卫生—肿瘤]